Simplify Asset Management Inc. Purchases Shares of 1,872,322 Cypherpunk Technologies $CYPH

Simplify Asset Management Inc. purchased a new stake in shares of Cypherpunk Technologies (NASDAQ:CYPH) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 1,872,322 shares of the company’s stock, valued at approximately $2,172,000.

A number of other large investors have also made changes to their positions in the company. HighTower Advisors LLC bought a new stake in shares of Cypherpunk Technologies during the 4th quarter valued at about $59,000. Sequoia Financial Advisors LLC bought a new stake in shares of Cypherpunk Technologies during the 4th quarter valued at about $56,000. Key Client Fiduciary Advisors LLC bought a new stake in shares of Cypherpunk Technologies during the 4th quarter valued at about $98,000. Finally, Acadian Asset Management LLC grew its stake in shares of Cypherpunk Technologies by 470.4% during the 1st quarter. Acadian Asset Management LLC now owns 1,280,531 shares of the company’s stock valued at $389,000 after purchasing an additional 1,056,047 shares during the period. 30.46% of the stock is currently owned by institutional investors.

Cypherpunk Technologies Stock Performance

NASDAQ CYPH opened at $1.20 on Monday. The stock’s 50 day moving average is $0.90 and its 200 day moving average is $1.02. Cypherpunk Technologies has a 12 month low of $0.23 and a 12 month high of $3.70. The stock has a market cap of $127.75 million, a PE ratio of -59.97 and a beta of -0.09.

Cypherpunk Technologies (NASDAQ:CYPH) last posted its quarterly earnings results on Monday, May 18th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.42).

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on CYPH shares. Wall Street Zen downgraded Cypherpunk Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings cut Cypherpunk Technologies from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Thursday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

About Cypherpunk Technologies

Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.